We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Next Generation Single Molecule Imaging to Transform In Vitro Diagnosis

By LabMedica International staff writers
Posted on 15 Jun 2023

A groundbreaking multi-omic platform designed for in vitro diagnosis can rapidly detect disease biomarkers, leading to earlier diagnoses for a variety of life-threatening illnesses. More...

The state-of-the-art platform is based on SMi Systems’ (Cambridge, UK) advanced super-resolution optical technology that boasts unrivaled spatial (1.6 nanometres) and temporal (0.5 milliseconds) resolution. SMi’s automated, high-precision optical technology provides the capability to view single molecule interactions in real-time. SMi is leveraging this huge leap in optical technology to develop a diagnostic device that can identify single molecules associated with both infectious and non-infectious diseases. When paired with AI, the platform offers unparalleled quantification of disease-associated single molecules. Furthermore, its capacity to simultaneously differentiate between various diseases from a single sample and process hundreds of samples in mere minutes makes it a highly efficient diagnostic tool. SMi has developed proof-of-principle instruments and also demonstrated their effectiveness in detecting infectious diseases.

Single molecule resolution enables diseases to be detected much earlier. The resolution levels offered by SMi's technology are unprecedented and can be tailored to any molecular target, allowing individual particles to be visualized and counted directly for the first time. This offers clinicians undeniable proof of the existence of molecules associated with either infectious or non-infectious diseases. The fully automated system requires less than a second per sample to provide a diagnosis, marking a considerable improvement over less precise lateral flow tests and PCR tests that can take several minutes or even hours. With the ability to process up to 384 samples in just a few minutes, this technology could become a game-changer, particularly for large-scale patient sample screenings in healthcare settings.

“We’ve proved the success of our new platform in both respiratory diseases and cancer biomarker diagnosis, but we’re only just scratching the surface of what is possible using our single molecule imaging technology,” said Dr Andrew Thompson, Chief Executive Officer (CEO) at SMi.

Related Links:
SMi Systems 


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Online QC Software
Acusera 24•7
Clinical Informatics Platform
CLARION™
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image

Anti-Lipid Antibody Biomarkers May Identify Early Lyme Disease and Persistent Symptoms

Lyme disease is often missed during its earliest and most treatable stage, while current serologic assays cannot distinguish active infection from prior exposure. Nearly half a million Americans are diagnosed... Read more

Industry

view channel
Im

Eurobio Scientific Completes Acquisition of CareDx Lab Products Division

Eurobio Scientific has closed the acquisition of CareDx AB in Sweden and its fully owned subsidiaries in the United States and Australia that constitute CareDx’s Lab Products division. The business will... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.